Julphar Ethiopia undertakes cGMP’sGap Analysis audit

Julphar Ethiopia, subsidiary of Julphar Gulf Pharmaceutical Industries in UAE, has undertaken the cGMP Gap Analysis audit, giving reassurance that the company complies with all appropriate quality regulations. The assessment was performed on September 1st and 2nd 2016 under the supervision of the Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA), the Ministry of Industry (MOI), the United Nations Industrial Development Organization (UNIDO) and the World Health Organization (WHO).

“The cGMP Gap Analysis audit is part of Julphar Ethiopia’s strategy to ensure our manufacturing plant adheres to the GMP rules and regulations,” said Mukemil Abdella, Country Director of Julphar Ethiopia. “We received the PIC/S GMP certification in the past, which has confirmed the high quality of our manufactured products, and this new assessment will confirm Julphar Ethiopia’s plant is a model to follow in the country.”

Taking into consideration the potential economic growth of Ethiopia, Julphar Gulf Pharmaceutical Industries inaugurated Julphar Ethiopia in 2013. The facility produces and distributes pharmaceutical products to the Ethiopian market – such as antibacterial, cough preparations, antidiabetic, diuretics, antiallergic, Hepatitis C medicines, multi-vitamins, etc.